---

Complete Guide to Pharmacology — From Foundations to Clinical Applications

---

PART 1: WHAT IS PHARMACOLOGY?

---

PART 2: PHARMACOKINETICS — ADME

A. Absorption

• Route of administration — IV bypasses absorption entirely (100% bioavailability); oral has first-pass metabolism
• pH and ionization — Weak acids absorb best in the stomach (low pH = nonionized form); weak bases absorb best in the small intestine (higher pH). Only the nonionized form crosses lipid membranes.
• Bioavailability (F) — Fraction of the administered dose that reaches systemic circulation unchanged

Example: A weakly basic drug (pKa 7.8) is mainly in the nonionized form at jejunal pH ~8.0, so it is best absorbed there. (Lippincott, p. 78)

B. Distribution

• Protein binding — Albumin binds acidic drugs; α1-acid glycoprotein binds basic drugs. Bound drug is pharmacologically inactive.
• Volume of Distribution (Vd) — How widely a drug spreads. High Vd = drug distributes extensively into tissues (chloroquine); Low Vd = drug stays in plasma (warfarin, heparin).
• Blood-Brain Barrier — Only lipid-soluble, non-protein-bound, small molecules penetrate the CNS.

C. Metabolism (Biotransformation)

• Phase I — Oxidation, reduction, hydrolysis via CYP450 enzymes. Converts drug to a more polar (water-soluble) compound; may activate prodrugs (codeine → morphine) or deactivate drugs.
• Phase II — Conjugation with glucuronic acid, sulfate, acetate, amino acids → highly water-soluble conjugates → excreted in urine/bile.

D. Excretion

• Renal — Glomerular filtration, tubular secretion, tubular reabsorption (pH-dependent). Alkalinizing urine traps acidic drugs (aspirin overdose treated with NaHCO₃).
• Biliary/fecal — Large molecular weight drugs (>300 Da) excreted via bile; can undergo enterohepatic recirculation.

Key PK Parameters

---

PART 3: RECEPTORS — THE COMPLETE PICTURE

What Is a Receptor?

"Pharmacodynamics describes the actions of a drug on the body. Most drugs exert effects, both beneficial and harmful, by interacting with specialized target macromolecules called receptors." (Lippincott, p. 82)

The Four Receptor Superfamilies

---

1. Ligand-Gated Ion Channels (Ionotropic Receptors) — Type I

• Structure: Transmembrane protein with an ion pore
• Speed: Milliseconds — fastest signaling
• Mechanism: Drug binds → channel opens → ions flow
• Examples:
  • Nicotinic ACh receptor (nAChR): Na⁺ influx / K⁺ efflux → action potential in muscle/neurons
  • GABA-A receptor: Cl⁻ influx → hyperpolarization → inhibition (benzodiazepines and barbiturates act here)
  • Glutamate (NMDA) receptor: Na⁺/Ca²⁺ influx → excitation (ketamine blocks this)
• Clinical drugs: Benzodiazepines (enhance GABA-A), succinylcholine (nAChR agonist), local anesthetics (block voltage-gated Na⁺ channels)

---

2. G Protein-Coupled Receptors (GPCRs) — Type II

• Structure: 7 transmembrane helices; intracellular G protein (α, β, γ subunits)
• Speed: Seconds to minutes

• Adrenoceptors (α1, α2, β1, β2, β3) — epinephrine, norepinephrine, salbutamol
• Muscarinic receptors (M1–M5) — acetylcholine, atropine
• Histamine receptors (H1, H2, H3, H4) — histamine, cetirizine, ranitidine
• Dopamine receptors (D1–D5) — levodopa, haloperidol, clozapine
• Opioid receptors (μ, κ, δ) — morphine, naloxone
• Serotonin receptors (5-HT1–7) — SSRIs, triptans, ondansetron

---

3. Enzyme-Linked Receptors (Receptor Tyrosine Kinases) — Type III

• Structure: Single transmembrane domain; intracellular kinase domain
• Mechanism: Ligand binds → receptor dimerizes → autophosphorylation → downstream phosphorylation cascade
• Speed: Minutes to hours
• Examples:
  • Insulin receptor — phosphorylates IRS proteins → GLUT4 translocation → glucose uptake
  • Growth hormone receptor — JAK/STAT pathway
  • EGF receptor — targeted by drugs like erlotinib (cancer)
  • VEGF receptor — targeted by bevacizumab (antiangiogenic therapy)

---

4. Intracellular (Nuclear) Receptors — Type IV

• Structure: Cytoplasmic or nuclear proteins; act as transcription factors
• Ligand requirement: Must be lipid-soluble to cross the cell membrane
• Speed: Hours to days — gene expression changes
• Second messengers: None; direct DNA binding
• Examples:
  • Glucocorticoid receptor — cortisol, prednisone, dexamethasone
  • Mineralocorticoid receptor — aldosterone, fludrocortisone
  • Thyroid hormone receptor — T3, T4
  • Sex hormone receptors — estrogen (ER), androgen (AR), progesterone (PR)
  • Retinoic acid receptor — Vitamin A, isotretinoin

Steroid hormones diffuse across membranes, bind cytoplasmic receptors → receptor-hormone complex translocates to nucleus → binds hormone response elements on DNA → alters gene transcription.

---

Receptor States — Active vs. Inactive

---

Types of Antagonism

1. Competitive (reversible): Binds same site as agonist; shifts dose-response curve right (↑ EC50), Emax unchanged. Overcome by increasing agonist concentration. Example: atropine blocking ACh at muscarinic receptors
2. Irreversible (noncompetitive): Binds covalently → permanently reduces Emax; EC50 unchanged. Cannot be overcome. Example: phenoxybenzamine at α-receptors
3. Allosteric antagonism: Binds a different site; changes receptor conformation → blocks agonist effect. Also ↓ Emax. Example: picrotoxin inside the GABA-A chloride channel
4. Functional (physiological) antagonism: Two drugs act at separate receptors with opposing effects. Example: epinephrine (β2 → bronchodilation) opposes histamine (H1 → bronchoconstriction)

---

Dose-Response Relationships

• Graded dose-response: As dose increases, response increases — used to measure potency (EC50) and efficacy (Emax).
• EC50 — dose producing 50% of maximum response = measure of potency (lower EC50 = more potent)
• Emax — maximum possible response = measure of efficacy
• Therapeutic Index (TI) = TD50 / ED50. A wide TI (e.g., penicillin) means more safety margin; narrow TI (e.g., digoxin, lithium, warfarin) requires therapeutic drug monitoring.

---

PART 4: HOW RECEPTORS INTERCONNECT EVERY CHAPTER OF PHARMACOLOGY

---

PART 5: DRUG GENERATIONS — WHAT DOES 1st, 2nd, 3rd GENERATION MEAN?

---

EXAMPLE 1: ANTIHISTAMINES (H1 Blockers)

"The second-generation H1 antagonists are used mainly for the treatment of allergic rhinitis and chronic urticaria... sedation occurred in only about 7% of subjects taking the second-generation agents [vs ~50% with first-generation]." (Katzung, p. 441)

---

EXAMPLE 2: BETA-BLOCKERS (β-Adrenoceptor Antagonists)

"The third-generation beta blocker drugs are cardioselective and have additional vasodilatory properties (nebivolol), used alone or in combination with α-receptor blockade (carvedilol)." (Harrison's, block 30)

"Cardioselective β-blockers that only block β1 receptors, such as metoprolol and atenolol, are preferred. All β-blockers are nonselective at high doses and can inhibit β2 receptors." (Lippincott, p. 418)

---

EXAMPLE 3: ANTIPSYCHOTICS (Dopamine/Serotonin Antagonists)

"First-generation antipsychotics are more likely to be associated with movement disorders known as extrapyramidal symptoms (EPS)... The second-generation antipsychotic drugs (SGAs) have a lower incidence of EPS but are associated with a higher risk of metabolic adverse effects, such as diabetes, hypercholesterolemia, and weight gain. The second-generation drugs owe their unique activity to blockade of both serotonin 5-HT2A and dopamine D2 receptors." (Lippincott, p. 612–613)

---

EXAMPLE 4: CEPHALOSPORINS (Antibiotic Generations)

---

PART 6: SAME DRUG — DIFFERENT RECEPTOR IN DIFFERENT SYSTEM = DIFFERENT USE AND SIDE EFFECT

---

EPINEPHRINE — One Drug, Many Receptors, Many Uses

---

PROPRANOLOL — Non-selective β-blocker

---

ATROPINE — Muscarinic Antagonist (same receptor M everywhere, different organ effects)

---

MORPHINE — μ-Opioid Receptor Agonist

---

METFORMIN — Non-receptor, but illustrates system-specific action

• Liver: ↓ gluconeogenesis (main effect) → lowers fasting glucose
• GI: Delayed absorption → weight-neutral, GI side effects (nausea, diarrhea)
• No β-cell stimulation → no hypoglycemia
• Kidney: Lactic acidosis risk if GFR <30 (reduced clearance)

---

PART 7: RECEPTOR INTERCONNECTIONS — THE BIG PICTURE

SYMPATHETIC ("fight or flight")
  └─ Norepinephrine / Epinephrine
      ├─ α1 (Gq) → vascular constriction, mydriasis, urinary retention
      ├─ α2 (Gi) → presynaptic inhibition, ↓ insulin, ↓ NE release
      ├─ β1 (Gs) → ↑ HR, ↑ contractility, ↑ renin, lipolysis
      ├─ β2 (Gs) → bronchodilation, vasodilation, glycogenolysis, uterine relaxation
      └─ β3 (Gs) → lipolysis in adipose

PARASYMPATHETIC ("rest and digest")
  └─ Acetylcholine
      ├─ M1 (Gq) → CNS cognition, gastric acid (ECL cells)
      ├─ M2 (Gi) → ↓ HR, ↓ conduction (SA/AV nodes)
      ├─ M3 (Gq) → gland secretion, smooth muscle contraction, bronchoconstriction, miosis
      ├─ M4 (Gi) → CNS modulation
      └─ M5 (Gq) → CNS/dopamine modulation

SOMATIC / NEUROMUSCULAR
  └─ ACh on Nicotinic (nAChR) — ion channel (Na⁺/K⁺) → skeletal muscle contraction

• Phenylephrine (α1 agonist) → nasal decongestant, raises BP
• Clonidine (α2 agonist) → lowers BP (reduces central NE release)
• Salbutamol (β2 agonist) → asthma bronchodilator
• Atenolol (β1 blocker) → lowers HR/BP
• Pilocarpine (M agonist) → treats glaucoma (increases aqueous drainage)
• Atropine (M antagonist) → treats bradycardia, dilates pupils
• Neostigmine (AChE inhibitor) → raises ACh at all muscarinic and nicotinic sites → treats myasthenia gravis, reverses neuromuscular blockade

---

PART 8: THERAPEUTIC INDEX AND DRUG SAFETY

---

SUMMARY: HOW TO THINK ABOUT ANY DRUG

1. What receptor/enzyme does it target? → determines mechanism
2. Is it an agonist, antagonist, partial agonist? → determines direction of effect
3. What is the receptor type (GPCR, ion channel, kinase, nuclear)? → determines speed and nature of signal
4. Where is that receptor expressed? → predicts both therapeutic effects AND side effects
5. What are its PK properties (lipid soluble? first pass? half-life? renal/hepatic clearance)? → determines dosing, routes, drug interactions

---